# Stial

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stial

- Industry: Industrial Machinery
- Headquarters: Wuxi, China
- Website: www.stial.cn
- Total disclosed funding: $14M
- Latest round: Series A (May 31, 2024)
- Investors on record: 2

## About

Founded in 2005 and based in Wuxi, China, Stial is a robotic technology company that focuses on the development of flexible grinding robots. The company has set up bases in Wuxi, Ningbo, and Anhui, an international business center in Hong Kong and a research and development center in Canada. It acquired more than 40 national patents. The core R&D team graduated from the University of Western Ontario, University of New Brunswick, University of Toronto, and Southeast University. In October 2023, Stial raised pre-series A+ funding. In May 2024, the company raised approximately CNY 100 million in series A funding.

The company's main products include flexible polishing robot workstations, AGV walking flexible polishing robots and robot sensing neural networks and touch, etc. Stial also developed PolishX flexible force control system and NextBrain AI mushroom cloud system. The company's F-PaaS business, a shared factory for grinding and polishing robots, can provide customers with grinding and polishing outsourcing services. Its products and services are used in automobile manufacturing, aerospace, military weapons, machinery and equipment, 3C digital, home furnishing, and other fields.

The company generates revenue by developing and providing flexible sanding robots.

Stial will focus on marketing and sales of terminal equipment and shared factories, R&D iterations, and the layout of humanoid robots based on grinding scenarios.

## Funding rounds

- Series A, May 31, 2024, $14M — Zheshang Venture Capital, China Aerospace Hi-Tech Investment

## Investors

- Zheshang Venture Capital (https://capitalatlas.ai/funds/zheshang-venture-capital) — Series A
- China Aerospace Hi-Tech Investment (https://capitalatlas.ai/funds/china-aerospace-hi-tech-investment) — Series A